This study was published in the September issue of 2014 Nature Cell Biology (I.F: 20.085) by Dr. Kang Y, Rumela Chakrabarti [I.F > 20.058] and others from the Princeton University, New Jersey 08544, USA
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: Anti-cancer stem cell therapeutics: Campothecin (CPT) inhibits mammary cancer stem cell proliferation via down regulation of Wnt receptor FZD7. This study may suggest that Campothecin, by up regulating its target gene, it may inhibit the Wnt pathway. Together, this study suggests that pharmacological formulations encompassing “Campothecin or its analogues” can be used to inhibit mammary tumor initiating cells.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, L., Anti-cancer stem cell therapeutics: Campothecin (CPT) inhibits mammary cancer stem cell proliferation via down regulation of Wnt receptor FZD7, 01/October/2014, 14.50, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at firstname.lastname@example.org
* Research cooperation